{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T17:11:22Z","timestamp":1770225082805,"version":"3.49.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,10,26]],"date-time":"2019-10-26T00:00:00Z","timestamp":1572048000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,26]],"date-time":"2019-10-26T00:00:00Z","timestamp":1572048000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00415-019-09593-6","type":"journal-article","created":{"date-parts":[[2019,10,26]],"date-time":"2019-10-26T10:02:31Z","timestamp":1572084151000},"page":"415-421","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A role for cannabinoids in the treatment of myotonia? Report of compassionate use in a small cohort of patients"],"prefix":"10.1007","volume":"267","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7291-5408","authenticated-orcid":false,"given":"Federica","family":"Montagnese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Wenninger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedikt","family":"Schoser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,26]]},"reference":[{"key":"9593_CR1","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3389\/fneur.2018.00303","volume":"9","author":"S Wenninger","year":"2018","unstructured":"Wenninger S, Montagnese F, Schoser B (2018) Core clinical phenotypes in myotonic dystrophies. Front Neurol 9:303. \nhttps:\/\/doi.org\/10.3389\/fneur.2018.00303","journal-title":"Front Neurol"},{"issue":"6","key":"9593_CR2","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/mus.24079.3","volume":"49","author":"J Mir\u00f3","year":"2014","unstructured":"Mir\u00f3 J, Gertz KJ, Carter GT, Jensen MP (2014) Pain location and intensity impacts function in persons with myotonic dystrophy type 1 and facioscapulohumeral dystrophy with chronic pain. Muscle Nerve 49(6):900\u2013905. \nhttps:\/\/doi.org\/10.1002\/mus.24079.3","journal-title":"Muscle Nerve"},{"issue":"4","key":"9593_CR3","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1212\/WNL.0b013e318260cbe6","volume":"79","author":"C Heatwole","year":"2012","unstructured":"Heatwole C, Bode R, Johnson N, Quinn C, Martens W, McDer MP, Rothrock N, Thornton C, Vickrey B, Victorson D, Mox-ley R (2012) Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1). Neurology 79(4):348\u2013357. \nhttps:\/\/doi.org\/10.1212\/WNL.0b013e318260cbe6","journal-title":"Neurology"},{"issue":"24","key":"9593_CR4","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1212\/WNL.0000000000002225","volume":"85","author":"C Heatwole","year":"2015","unstructured":"Heatwole C, Johnson N, Bode R, Dekdebrun J, Dilek N, Hilbert JE, Luebbe E, Martens W, McDermott MP, Quinn C, Rothrock N, Thornton C, Vickrey BG, Victorson D, Moxley RT (2015) Patient-reported impact of symptoms in myotonic dystrophy type 2 (PRISM-2). Neurology 85(24):2136\u20132146. \nhttps:\/\/doi.org\/10.1212\/WNL.0000000000002225","journal-title":"Neurology"},{"issue":"24","key":"9593_CR5","doi-asserted-by":"publisher","first-page":"e251","DOI":"10.1212\/WNL.0b013e318296e905","volume":"80","author":"NE Johnson","year":"2013","unstructured":"Johnson NE, Heatwole CR (2013) Teaching video neuroimages: trapezius myotonia percussion sign in myotonic dystrophy type 2. Neurology 80(24):e251. \nhttps:\/\/doi.org\/10.1212\/WNL.0b013e318296e905","journal-title":"Neurology"},{"issue":"1","key":"9593_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/mus.22249","volume":"45","author":"KI Suokas","year":"2012","unstructured":"Suokas KI, Haanp\u00e4\u00e4 M, Kautiainen H, Udd B, Hietaharju AJ (2012) Pain in patients with myotonic dystrophy type 2: a postal survey in Finland. Muscle Nerve 45(1):70\u201374. \nhttps:\/\/doi.org\/10.1002\/mus.22249","journal-title":"Muscle Nerve"},{"key":"9593_CR7","first-page":"1889","volume":"22","author":"VA Sansone","year":"2016","unstructured":"Sansone VA (2016) The dystrophic and nondystrophic myotonias. Continuum 22:1889\u20131915","journal-title":"Continuum"},{"issue":"9","key":"9593_CR8","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1055\/a-0635-8285","volume":"86","author":"F Montagnese","year":"2018","unstructured":"Montagnese F, Schoser B (2018) Dystrophic and non-dystrophic myotonias. Fortschr Neurol Psychiatr 86(9):575\u2013583. \nhttps:\/\/doi.org\/10.1055\/a-0635-8285","journal-title":"Fortschr Neurol Psychiatr"},{"issue":"2","key":"9593_CR9","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/cphy.c140062","volume":"5","author":"SC Cannon","year":"2015","unstructured":"Cannon SC (2015) Channelopathies of skeletal muscle excitability. Compr Physiol 5(2):761\u2013790. \nhttps:\/\/doi.org\/10.1002\/cphy.c140062","journal-title":"Compr Physiol"},{"key":"9593_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.expneurol.2013.12.005","volume":"253","author":"JR Trivedi","year":"2014","unstructured":"Trivedi JR, Cannon SC, Griggs RC (2014) Nondystrophic myotonia: challenges and future directions. Exp Neurol 253:28\u201330. \nhttps:\/\/doi.org\/10.1016\/j.expneurol.2013.12.005","journal-title":"Exp Neurol"},{"issue":"Pt 1","key":"9593_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/brain\/awp294","volume":"133","author":"E Matthews","year":"2010","unstructured":"Matthews E, Fialho D, Tan SV, Venance SL, Cannon SC, Sternberg D, Fontaine B, Amato AA, Barohn RJ, Griggs RC, Hanna MG, CINCH Investigators (2010) The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment. Brain 133(Pt 1):9\u201322. \nhttps:\/\/doi.org\/10.1093\/brain\/awp294","journal-title":"Brain"},{"issue":"13","key":"9593_CR12","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1001\/jama.2012.12607","volume":"308","author":"JM Statland","year":"2012","unstructured":"Statland JM, Bundy BN, Wang Y, Rayan DR, Trivedi JR, Sansone VA, Salajegheh MK, Venance SL, Ciafaloni E, Matthews E, Meola G, Herbelin L, Griggs RC, Barohn RJ, Hanna MG, Consortium for Clinical Investigation of Neurologic Channelopathies (2012) Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. JAMA 308(13):1357\u20131365. \nhttps:\/\/doi.org\/10.1001\/jama.2012.12607","journal-title":"JAMA"},{"issue":"22","key":"9593_CR13","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1001\/jama.2018.18020","volume":"320","author":"BC Stunnenberg","year":"2018","unstructured":"Stunnenberg BC, Raaphorst J, Groenewoud HM, Statland JM, Griggs RC, Woertman W, Stegeman DF, Timmermans J, Trivedi J, Matthews E, Saris CGJ, Schouwenberg BJ, Drost G, van Engelen BGM, van der Wilt GJ (2018) Effect of mexiletine on muscle stiffness in patients with nondystrophic myotonia evaluated using aggregated N-of-1 trials. JAMA 320(22):2344\u20132353. \nhttps:\/\/doi.org\/10.1001\/jama.2018.18020","journal-title":"JAMA"},{"issue":"2","key":"9593_CR14","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/mus.26372","volume":"59","author":"S Lorusso","year":"2019","unstructured":"Lorusso S, Kline D, Bartlett A, Freimer M, Agriesti J, Hawash AA, Rich MM, Kissel JT, David AW (2019) Open-label trial of ranolazine for the treatment of paramyotonia congenita. Muscle Nerve 59(2):240\u2013243. \nhttps:\/\/doi.org\/10.1002\/mus.26372","journal-title":"Muscle Nerve"},{"issue":"9","key":"9593_CR15","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1093\/brain\/awx192","volume":"140","author":"G Andersen","year":"2017","unstructured":"Andersen G, Hedermann G, Witting N, Duno M, Andersen H, Vissing J (2017) The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study. Brain 140(9):2295\u20132305. \nhttps:\/\/doi.org\/10.1093\/brain\/awx192","journal-title":"Brain"},{"issue":"03","key":"9593_CR16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1055\/s-0043-125352","volume":"45","author":"C Schneider-Gold","year":"2018","unstructured":"Schneider-Gold C, Weber F, Schoser B, Ellrichmann G, Quasthoff S, Lehmann-Horn F, Sinnreich M (2018) Myotone Dystrophien, nicht dystrophe Myotonien und periodische Paralysen. Aktuelle Neurologie 45(03):167\u2013177. \nhttps:\/\/doi.org\/10.1055\/s-0043-125352","journal-title":"Aktuelle Neurologie"},{"issue":"Pt 7","key":"9593_CR17","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1093\/brain\/awt133","volume":"136","author":"JR Trivedi","year":"2013","unstructured":"Trivedi JR, Bundy B, Statland J, Salajegheh M, Rayan DR, Venance SL, Wang Y, Fialho D, Matthews E, Cleland J, Gorham N, Herbelin L, Cannon S, Amato A, Griggs RC, Hanna MG, Barohn RJ, CINCH Consortium (2013) Non-dystrophic myotonia: prospective study of objective and patient reported outcomes. Brain 136(Pt 7):2189\u20132200","journal-title":"Brain"},{"issue":"2","key":"9593_CR18","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1007\/s00415-018-9159-2","volume":"266","author":"F Montagnese","year":"2019","unstructured":"Montagnese F, White M, Klein A, Stahl K, Wenninger S, Schoser B (2019) Cannabis use in myotonic dystrophy patients in Germany and USA: a pilot survey. J Neurol 266(2):530\u2013532. \nhttps:\/\/doi.org\/10.1007\/s00415-018-9159-2","journal-title":"J Neurol"},{"key":"9593_CR19","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1097\/j.pain.000000000000129329847469","volume":"159","author":"E Stockings","year":"2018","unstructured":"Stockings E, Campbell G, Hall WD et al (2018) Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain 159:1932\u20131954. \nhttps:\/\/doi.org\/10.1097\/j.pain.000000000000129329847469","journal-title":"Pain"},{"key":"9593_CR20","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1001\/jama.2015.6358","volume":"313","author":"PF Whiting","year":"2015","unstructured":"Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV et al (2015) Cannabinoids for medical use. JAMA 313:2456","journal-title":"JAMA"},{"key":"9593_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ejphar.2014.10.016","volume":"745","author":"A Bag\u00fc\u00e9s","year":"2014","unstructured":"Bag\u00fc\u00e9s A, Mart\u00edn MI, S\u00e1nchez-Robles EM (2014) Involvement of central and peripheral cannabinoid receptors on antinociceptive effect of tetrahydrocannabinol in muscle pain. Eur J Pharmacol 745:69\u201375. \nhttps:\/\/doi.org\/10.1016\/j.ejphar.2014.10.016","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"9593_CR22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.bbrc.2007.09.099","volume":"364","author":"P Cavuoto","year":"2007","unstructured":"Cavuoto P, McAinch AJ, Hatzinikolas G, Janovsk\u00e1 A, Game P, Wittert GA (2007) The expression of receptors for endocannabinoids in human and rodent skeletal muscle. Biochem Biophys Res Commun 364(1):105\u2013110","journal-title":"Biochem Biophys Res Commun"},{"issue":"9\u201310","key":"9593_CR23","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.nmd.2005.07.002","volume":"15","author":"E Hammar\u00e9n","year":"2005","unstructured":"Hammar\u00e9n E, Kjellby-Wendt G, Lindberg C (2005) Quantification of mobility impairment and self-assessment of stiffness in patients with myotonia congenita by the physiotherapist. Neuromuscul Disord 15(9\u201310):610\u2013617","journal-title":"Neuromuscul Disord"},{"issue":"365","key":"9593_CR24","doi-asserted-by":"publisher","first-page":"l1141","DOI":"10.1136\/bmj.l1141","volume":"4","author":"TP Freeman","year":"2019","unstructured":"Freeman TP, Hindocha C, Green SF, Bloomfield MAP (2019) Medicinal use of cannabis based products and cannabinoids. BMJ 4(365):l1141. \nhttps:\/\/doi.org\/10.1136\/bmj.l1141","journal-title":"BMJ"},{"issue":"Suppl 1","key":"9593_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1365-2826.2008.01671.x","volume":"20","author":"K Mackie","year":"2008","unstructured":"Mackie K (2008) Cannabinoid receptors: where they are and what they do. J Neuroendocrinol 20(Suppl 1):10\u201314. \nhttps:\/\/doi.org\/10.1111\/j.1365-2826.2008.01671.x","journal-title":"J Neuroendocrinol"},{"issue":"1","key":"9593_CR26","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/npp.2017.209","volume":"43","author":"DL Boggs","year":"2018","unstructured":"Boggs DL, Nguyen JD, Morgenson D, Taffe MA, Ranganathan M (2018) Clinical and preclinical evidence for functional interactions of cannabidiol and \u03949-tetrahydrocannabinol. Neuropsychopharmacology 43(1):142\u2013154. \nhttps:\/\/doi.org\/10.1038\/npp.2017.209","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"9593_CR27","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.tips.2015.02.008","volume":"36","author":"M Maccarrone","year":"2015","unstructured":"Maccarrone M, Bab I, B\u00edr\u00f3 T, Cabral GA, Dey SK, Di Marzo V, Konje JC, Kunos G, Mechoulam R, Pacher P, Sharkey KA, Zimmer A (2015) Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci 36(5):277\u2013296. \nhttps:\/\/doi.org\/10.1016\/j.tips.2015.02.008","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"9593_CR28","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","volume":"153","author":"RG Pertwee","year":"2008","unstructured":"Pertwee RG (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 153(2):199\u2013215","journal-title":"Br J Pharmacol"},{"issue":"5","key":"9593_CR29","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S1474-4422(19)30032-8","volume":"18","author":"D Friedman","year":"2019","unstructured":"Friedman D, French JA, Maccarrone M (2019) Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders. Lancet Neurol 18(5):504\u2013512. \nhttps:\/\/doi.org\/10.1016\/S1474-4422(19)30032-8","journal-title":"Lancet Neurol"},{"issue":"4","key":"9593_CR30","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1080\/17512433.2017.1292849","volume":"10","author":"M Maccarrone","year":"2017","unstructured":"Maccarrone M, Maldonado R, Casas M, Henze T, Centonze D (2017) Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others? Expert Rev Clin Pharmacol 10(4):443\u2013455. \nhttps:\/\/doi.org\/10.1080\/17512433.2017.1292849","journal-title":"Expert Rev Clin Pharmacol"},{"key":"9593_CR31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.pharmthera.2017.02.041","volume":"175","author":"S Pisanti","year":"2017","unstructured":"Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, Abate M, Faggiana G, Proto MC, Fiore D, Laezza C, Bifulco M (2017) Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol Ther 175:133\u2013150. \nhttps:\/\/doi.org\/10.1016\/j.pharmthera.2017.02.041","journal-title":"Pharmacol Ther"},{"issue":"2","key":"9593_CR32","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1097\/WNF.0000000000000132","volume":"39","author":"K Fija\u0142","year":"2016","unstructured":"Fija\u0142 K, Filip M (2016) Clinical\/therapeutic approaches for cannabinoid ligands in central and peripheral nervous system diseases: mini review. Clin Neuropharmacol 39(2):94\u2013101","journal-title":"Clin Neuropharmacol"},{"issue":"24","key":"9593_CR33","doi-asserted-by":"publisher","first-page":"7381","DOI":"10.1113\/JP272449","volume":"594","author":"T Ol\u00e1h","year":"2016","unstructured":"Ol\u00e1h T, Bodn\u00e1r D, T\u00f3th A, Vincze J, Fodor J, Reischl B, Kov\u00e1cs A, Ruzsnavszky O, Dienes B, Szentesi P, Friedrich O, Csernoch L (2016) Cannabinoid signalling inhibits sarcoplasmic Ca2+ release and regulates excitation-contraction coupling in mammalian skeletal muscle. J Physiol 594(24):7381\u20137398","journal-title":"J Physiol"},{"issue":"10","key":"9593_CR34","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1111\/bph.14460","volume":"176","author":"FA Iannotti","year":"2019","unstructured":"Iannotti FA, Pagano E, Moriello AS, Alvino FG, Sorrentino NC, D'Orsi L, Gazzerro E, Capasso R, De Leonibus E, De Petrocellis L, Di Marzo V (2019) Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice. Br J Pharmacol 176(10):1568\u20131584. \nhttps:\/\/doi.org\/10.1111\/bph.14460","journal-title":"Br J Pharmacol"},{"issue":"2","key":"9593_CR35","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11910-018-0814-x","volume":"18","author":"S Nielsen","year":"2018","unstructured":"Nielsen S, Germanos R, Weier M, Pollard J, Degenhardt L, Hall W, Buckley N, Farrell M (2018) The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews. Curr Neurol Neurosci Rep 18(2):8. \nhttps:\/\/doi.org\/10.1007\/s11910-018-0814-x","journal-title":"Curr Neurol Neurosci Rep"},{"key":"9593_CR36","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ebiom.2016.03.017","volume":"7","author":"R Moshourab","year":"2016","unstructured":"Moshourab R, Palada V, Grunwald S, Grieben U, Lewin GR, Spuler S (2016) A molecular signature of myalgia in myotonic dystrophy 2. EBioMedicine 7:205\u2013211. \nhttps:\/\/doi.org\/10.1016\/j.ebiom.2016.03.017\n\nEpub 2016 Mar 14","journal-title":"EBioMedicine"},{"issue":"13","key":"9593_CR37","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1212\/WNL.0000000000004420","volume":"89","author":"JE Hilbert","year":"2017","unstructured":"Hilbert JE, Barohn RJ, Clemens PR, Luebbe EA, Martens WB, McDermott MP, Parkhill AL, Tawil R, Thornton CA, Moxley RT, National Registry Scientific Advisory Committee\/Investigators (2017) High frequency of gastrointestinal manifestations in myotonic dystrophy type 1 and type 2. Neurology 89(13):1348\u20131354. \nhttps:\/\/doi.org\/10.1212\/WNL.0000000000004420","journal-title":"Neurology"},{"key":"9593_CR38","doi-asserted-by":"publisher","first-page":"G78","DOI":"10.1152\/ajpgi.90285.2008","volume":"295","author":"M Duncan","year":"2008","unstructured":"Duncan M et al (2008) Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats. Am J Physiol Gastrointest Liver Physiol 295:G78\u2013G87","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"1","key":"9593_CR39","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1089\/can.2016.0007","volume":"1","author":"M Sexton","year":"2016","unstructured":"Sexton M, Cuttler C, Finnell JS, Mischley LK (2016) A crosssectional survey of medical cannabis users: patterns of use and perceived efficacy. Cannabis Cannabinoid Res 1(1):131\u2013138. \nhttps:\/\/doi.org\/10.1089\/can.2016.0007","journal-title":"Cannabis Cannabinoid Res"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09593-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-019-09593-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09593-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T23:11:29Z","timestamp":1603581089000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-019-09593-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,26]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["9593"],"URL":"https:\/\/doi.org\/10.1007\/s00415-019-09593-6","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,26]]},"assertion":[{"value":"29 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"FM, KS, and SW have no conflicts of interest. BS is a scientific advisor of Nexien BioPharma, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study followed the principles of the Declaration of Helsinki. As open labelled compassionate use treatment, no formal IRB approval was submitted.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard"}}]}}